Trial Watch—Oncolytic viruses and cancer therapy

Jonathan Pol, Aitziber Buqué, Fernando Aranda, Norma Bloy, Isabelle Cremer, Alexander Eggermont, Philippe Erbs, Jitka Fucikova, Jérôme Galon, Jean Marc Limacher, Xavier Preville, Catherine Sautès-Fridman, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journalReview articlepeer-review

98 Scopus citations

Abstract

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.

Original languageEnglish
Pages (from-to)e1117740
JournalOncoimmunology
Volume5
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Keywords

  • Cavatak™
  • GM-CSF
  • JX-594
  • ONCOS-102
  • Reolysin
  • talimogene laherparepvec

Fingerprint

Dive into the research topics of 'Trial Watch—Oncolytic viruses and cancer therapy'. Together they form a unique fingerprint.

Cite this